FR2563435A1 - Process which makes it possible to obtain products that increase the defence capacities of biological organisms - Google Patents
Process which makes it possible to obtain products that increase the defence capacities of biological organisms Download PDFInfo
- Publication number
- FR2563435A1 FR2563435A1 FR8406638A FR8406638A FR2563435A1 FR 2563435 A1 FR2563435 A1 FR 2563435A1 FR 8406638 A FR8406638 A FR 8406638A FR 8406638 A FR8406638 A FR 8406638A FR 2563435 A1 FR2563435 A1 FR 2563435A1
- Authority
- FR
- France
- Prior art keywords
- products
- specific
- deconcentration
- substance
- capacities
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title abstract description 15
- 230000008569 process Effects 0.000 title abstract description 11
- 239000000126 substance Substances 0.000 claims abstract description 41
- 230000001506 immunosuppresive effect Effects 0.000 claims abstract description 15
- 241001465754 Metazoa Species 0.000 claims abstract description 13
- 230000004060 metabolic process Effects 0.000 claims abstract description 9
- 244000005700 microbiome Species 0.000 claims abstract description 7
- 230000036039 immunity Effects 0.000 claims abstract description 5
- 230000004048 modification Effects 0.000 claims abstract description 5
- 238000012986 modification Methods 0.000 claims abstract description 5
- 206010062016 Immunosuppression Diseases 0.000 claims abstract description 4
- 230000006978 adaptation Effects 0.000 claims abstract description 4
- 230000003308 immunostimulating effect Effects 0.000 claims description 11
- 230000007123 defense Effects 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 230000002519 immonomodulatory effect Effects 0.000 claims description 6
- 230000009471 action Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 241001133184 Colletotrichum agaves Species 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 230000000781 anti-lymphocytic effect Effects 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 229960001438 immunostimulant agent Drugs 0.000 description 4
- 239000003022 immunostimulating agent Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- -1 ecratratin A Natural products 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- ZRWPUFFVAOMMNM-UHFFFAOYSA-N Patulin Chemical compound OC1OCC=C2OC(=O)C=C12 ZRWPUFFVAOMMNM-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000002625 immunotoxic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229960001614 levamisole Drugs 0.000 description 2
- 231100000355 lymphocytotoxic Toxicity 0.000 description 2
- 230000001391 lymphocytotoxic effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- YLDCUKJMEKGGFI-QCSRICIXSA-N 4-acetamidobenzoic acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 YLDCUKJMEKGGFI-QCSRICIXSA-N 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002961 Aplasia Diseases 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical class CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 102100021906 Cyclin-O Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 231100000678 Mycotoxin Toxicity 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 108010033737 Pokeweed Mitogens Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- BXFOFFBJRFZBQZ-QYWOHJEZSA-N T-2 toxin Chemical compound C([C@@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@H]1[C@]3(COC(C)=O)C[C@@H](C(=C1)C)OC(=O)CC(C)C)O2 BXFOFFBJRFZBQZ-QYWOHJEZSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 208000014306 Trophic disease Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000567 anti-anemic effect Effects 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940045713 antineoplastic alkylating drug ethylene imines Drugs 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- XVIWVTWNQQUGQI-UHFFFAOYSA-L disodium;sulfanylidenemethanediolate Chemical compound [Na+].[Na+].[O-]C([O-])=S XVIWVTWNQQUGQI-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000403 immunocorrecting effect Effects 0.000 description 1
- 230000000043 immunodepressive effect Effects 0.000 description 1
- 230000001031 immunopharmacological effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 231100000110 immunotoxic Toxicity 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 239000003621 irrigation water Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 231100000373 leucotoxic Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000002624 leukotoxic effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- JABGXPCRNXUENL-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1N=CNC2=NC=N[C]12 JABGXPCRNXUENL-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- SOIXHYGGJDCTEA-UHFFFAOYSA-N n,n'-bis[bis(aziridin-1-yl)phosphoryl]-n,n'-dimethylethane-1,2-diamine Chemical compound C1CN1P(=O)(N1CC1)N(C)CCN(C)P(=O)(N1CC1)N1CC1 SOIXHYGGJDCTEA-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N purine-6-thione Natural products S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229940120731 pyruvaldehyde Drugs 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 239000000724 thymus hormone Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N61/00—Biocides, pest repellants or attractants, or plant growth regulators containing substances of unknown or undetermined composition, e.g. substances characterised only by the mode of action
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
DESCRIPTION
La présente invention consiste en un procédé qui permet d'obtenir des produits ayant notamment comme propriété d'augmenter les capacités de défenses et d'adaptation des organismes traités.Chez l'homme et l'animal,ce procédé consiste à déconcentrer ou à diluer les substances définies en biologie par leurs pro priétés immunosuppressives ou immunodépressives,ou (et) immunomodulatrices.DESCRIPTION
The present invention consists of a process which makes it possible to obtain products having in particular the property of increasing the defense and adaptation capacities of the treated organisms. In humans and animals, this process consists in deconcentrating or diluting substances defined in biology by their immunosuppressive or immunosuppressive, or (and) immunomodulatory properties.
Les substances immunodépressives ou immunosuppressives se définissent en biologie comme étant des substances provoquant une diminution des capacités de défenses de l'organisme quelle qu'en soit l'origine et ceci à une dose que nous appellerons la Dose Immunosuppressive et que nous noterons sous forme abrégée D.I. Immunosuppressive or immunosuppressive substances are defined in biology as being substances causing a decrease in the defenses of the organism whatever its origin and this at a dose which we will call the Immunosuppressive Dose and which we will note in abridged form DI
Su.-Cette immunodépression s'accompagne entres autres d'une grande sensibilité aux infections, aux inflammations; et, dans les cas graves,d'une lyse des cellules et tissus (par exemple:lyse hépatique,thymique,splénique,rénale,aplasie médullaire,leucopénie, anémie etc...).Su.-This immunosuppression is accompanied among others by a great sensitivity to infections, to inflammations; and, in severe cases, lysis of cells and tissues (for example: hepatic, thymic, splenic, renal lysis, bone marrow aplasia, leukopenia, anemia, etc.).
Le procédé conforme à l'invention consiste à déconcentrer la substance de telle sorte qu 'à partir de la millième partie (dix puissance moins trois:notée 10 -3 )de la D.I.Su. (soit déconcentration supérieure ou égale à 10 -3 D.I.Su.),cette même substance perd son activité immunotoxique pour se comporter comme un nouveau produit se définissant par une activité pharmacologique très intéressante::notamment immunostimulante (c'est-àdire augmentant ou favorisant les défenses spécifiques et non spécifiques de l'organisme),eutrophique sur les cellules et tissus concerné(e)s (ctest-à-dire améliorant le fonctionnement,le métabolisme de ces cellules et tissus),eubiotique (c'est-à-dire
Dermettant de recouvrer l'état de symbiose qui définit l'état de santé).The method according to the invention consists in deconcentrating the substance so that from the thousandth part (ten power minus three: noted 10 -3) of the DISu. (or deconcentration greater than or equal to 10 -3 DISu.), this same substance loses its immunotoxic activity to behave like a new product which is defined by a very interesting pharmacological activity :: in particular immunostimulant (that is to say increasing or favoring specific and non-specific defenses of the organism), eutrophic on the cells and tissues concerned (ie improving the functioning, the metabolism of these cells and tissues), eubiotic (i.e.
Allowing to recover the state of symbiosis which defines the state of health).
La réalisation pratique de ces déconcentrations est à la portée de tout homme de l'art,tous les procédés étant possibles.On peut par exemple utiliser les techniques de micro dosage pondéral ou de microdosage de l'activité biologique de la substance selon des normes standard .On peut également procéder par dilutions suc cessives à partir de la D.I.Su.
Toutes ces oporations sont autornatisable rendant possible une industrialisation.The practical realization of these deconcentrations is within the reach of any person skilled in the art, all the methods being possible. One can for example use the techniques of micro weight assay or microdosing of the biological activity of the substance according to standard standards. We can also proceed by successive dilutions from the DISu.
All these oporations are autornatisable making industrialization possible.
I1 est possible l'associer plusieurs déconcentrations soit aans la mEme présentation, soit dans des présentations séparées.Ces dift- rentes déconcentrations peuvent Autre administrées en meme temps ou à des instants différents.On peut également associer plusieurs substan ces en meme temps en une seule et même déconcentration ou à des déconcentrations multiples dès lors qu'elles sont supérieures ou égales à la millième partie de la D.I.Su. de chaque substance.Toutes les substances immunosunpressives ou immunodépressives ou imeuno- toxiques peuvent être utilisées comme substance de base à déconcen trek, que celle-ci soit d'origine minérale,végétale, animale,humai- ne ou qu'il s' agisse de produits de synthèse ou dthémisynthèse.Ci- tons à titre d'exemples non limitatifs:les agents alcoylants(agents ayant la proriété d'agir sur le noyau de la cellule et son acide désoxyribonucléique tels que 1 'yperite, le cyclopho aphamide, le chlorambucil,la méthylbisdisamine,l' acide chloroéthyhaminophényl,le melphalan,les éthylène-imines,les dérivés du busulfan etc...);;les antimétabolites(agents qui agissent sur certaines étapes de la synthèse des acides nucléiques ou d'autres constituants ou fonctions essentiels(elles) de la cellule tels que les antifoliques,les antipyrimidiques,les antipuriques par exemple l'améthoptérine,la 6 mercaptopurine,l'azathioprine,le 5 fluoroturacile etc...);les substances extraites de microorganismes et leurs dérivés tels que l'actinomycine D ou C,la rubidomycine,l'adriamycine,la bléomycine,la mitomycine CA, la mithramycine etc...; les mycotoxines telles que les aflatoxines, la T 2 toxine,l'echratoxine A,la patuline etc...;les substances extraites des végétaux telles que la vincristine,la vincaleucoblastine,la vindesine,l' épipodophylotoxine etc...;les produits de synthèse tels que la méthylhydrazine,l'hydroxyurée,le SCNU,le CCNU,le pyruvaldéhyde etc... ;les substances d'origine animale telles que les sérums antilymphocytaires,les immunoglobulines antilymphocytes humains etc... ;les substances synthétisées par certains tissus telles que les anticorps monoclonaux;les substances d'origine humaine telles que les hormones immunodépressives;;d'autres substances immunotoxiques telles que les venins,les lectines,la phytohemagglutinine,la concanavaline A,le pokeweed mitogen,la ricine;l' abrine,modeccine,le cisplatinum, la L-Asparaginase,la lomustine etc... It is possible to associate several deconcentrations either in the same presentation, or in separate presentations. These different deconcentrations can Other administered at the same time or at different times. We can also associate several substances at the same time in one and even deconcentration or multiple deconcentrations when they are greater than or equal to the thousandth part of the DISu. of each substance.All immunosunpressive or immunosuppressive or imeunotoxic substances can be used as basic substance to deconcen trek, whether it is of mineral, vegetable, animal, human origin or whether it is Synthetic or demisisynthesis products. Citations by way of nonlimiting examples: alkylating agents (agents which are said to act on the nucleus of the cell and its deoxyribonucleic acid such as yperite, cyclopho aphamide, chlorambucil , methylbisdisamine, chloroethyhaminophenyl acid, melphalan, ethyleneimines, busulfan derivatives etc ...); antimetabolites (agents which act on certain stages of the synthesis of nucleic acids or other constituents or functions essential (they) of the cell such as antifolics, antipyrimidics, antipurics for example amethopterin, 6 mercaptopurine, azathioprine, 5 fluoroturacil etc ...); substances extracted from microorganisms and l eurs derivatives such as actinomycin D or C, rubidomycin, adriamycin, bleomycin, mitomycin CA, mithramycin etc ...; mycotoxins such as aflatoxins, T 2 toxin, ecratratin A, patulin etc ...; substances extracted from plants such as vincristine, vincaleucoblastine, vindesine, epipodophylotoxin etc ...; products synthetic substances such as methylhydrazine, hydroxyurea, SCNU, CCNU, pyruvaldehyde etc ...; substances of animal origin such as antilymphocyte sera, human antilymphocyte immunoglobulins etc ...; substances synthesized by some tissues such as monoclonal antibodies; substances of human origin such as immunosuppressive hormones; other immunotoxic substances such as venoms, lectins, phytohemagglutinin, concanavalin A, pokeweed mitogen, ricin; abrin , modeccine, cisplatinum, L-Asparaginase, lomustine etc ...
En fait,toutes les substances immunosuppressives ou immunodépressives se comportent en raison de la déconcentration comme des immunostimulants immunocorrecteurs;l'action eutrophique de chacun de ces immunostimulants est à la fois générale et particulière sur tel ou tel tissu plus privilégié,ce qui est fonction du métabolisme et de l'immunopharmacologie du produit.In fact, all immunosuppressive or immunosuppressive substances behave as a result of deconcentration like immunocorrective immunostimulants; the eutrophic action of each of these immunostimulants is both general and particular on such or such more privileged tissue, which depends on the metabolism and immunopharmacology of the product.
Ainsi,si l'on a à traiter un suet infecté chronique ou aigu, on s'adressera préférentiellement comme substance de base à dé-concentrer aux immunodépresseurs dont on connalt 1'action sur le X ts; système lymphoïde tels que le chlorambucil,l'azathioprine,la 6'nrercaptopurine,les sérums antilymphocytaires, le cyclophosphamide etc...Autres exemples::on counatt l'affinité de la vinCristine pour le système nerveux, du cyclophosphamide pour les phanères et les organes reproducteurs etc...Si l'on désire stimuler plus particulièrement telle ou telle clas- se,sous-classe ou tel ou tel clone de cellules,on recourra aux anticorps monoclonaux correspondants. Thus, if one has to treat an infected chronic or acute suet, one will preferentially be addressed like basic substance to deconcentrate with the immunosuppressants whose action is known on the X ts; lymphoid system such as chlorambucil, azathioprine, 6'nrercaptopurine, antilymphocytic sera, cyclophosphamide etc ... Other examples: on counatt the affinity of vinCristine for the nervous system, of cyclophosphamide for the appendages and reproductive organs etc ... If one wishes to stimulate more particularly such or such class, subclass or such or such clone of cells, one will resort to the corresponding monoclonal antibodies.
On procèdera de même concernant les associations de produits différents se basant pour le choix de l'association des produits sur la synergie d'action métabolique ou immunopharmacologique de l'association. The same will be done for the associations of different products based on the choice of the association of the products on the synergy of metabolic or immunopharmacological action of the association.
L'ensemble des produits définis par le procédé conforme à l'invention constitue des médicaments très utiles en thérapeutique.Notamment,ils présentent la propriété de stimuler les défenses spécifiques et non spécifiques de l'organisme traité (immunostimulation ou immunocorrection spécifique et non spécifique).leur champ d'application chez l'homme et l'animal est donc très vaste.Ils pourront être en fait indiqués dans toutes pathologies quelle qu'en soit la nature lorsque l'on voudra stimuler les forces de guérison de l'organisme.Il s'agit d'une thérapeutique de terrain qui pourra trouver des indications multiples par exemple,et de manière non limitative, dans les maladies infectieuses, inflammatoires, autoimmunes, dégênératives, de sclérose ou de sénescence physiologique ou prematurée,mQta- boliques,trophiques etc ...Cette thérapeutique est destinée à remplacer les thérapeutiques substitutives qui ne font qu'apporter de manière artificielle un effet biologique dans un or ganisme qui a perdu une capacité ou qui tarde à la recouvrer ou à la promouvoir(substances antibiotiques, antiseptiques,antiin flammatoires,horm M hérapies substitutives etc...) ce qui,à court, moyen et long terme,risque d'avoir un effet dépresseur sur les capacités de défense et d'autoguérison de cet organisme et sur sa symbiose. All the products defined by the process in accordance with the invention constitute very useful drugs in therapy. In particular, they have the property of stimulating the specific and non-specific defenses of the organism treated (immunostimulation or specific and non-specific immunocorrection) .their field of application in humans and animals is therefore very wide. They may in fact be indicated in all pathologies of whatever nature when one wishes to stimulate the healing forces of the organism. It is a field therapy which can find multiple indications for example, and without limitation, in infectious, inflammatory, autoimmune, degenerative, sclerosis or physiological or premature senescence, metabolic, trophic diseases. etc ... This therapy is intended to replace replacement therapies which only artificially provide a biological effect in an organism which has lost an ability or that is slow to recover or promote it (antibiotic substances, antiseptics, anti-inflammatory drugs, horm M replacement therapies etc ...) which, in the short, medium and long term, may have a depressant effect on the defense and self-healing capacities of this organism and its symbiosis.
L'aide apportée par les explorations biologiques,particulièrement celles explorant l'immunité et le terrain(tests immunitaires,profils protéiques par exemple)permettra de suivre l'évo- lution et d'orienter le traitement. The help provided by biological explorations, particularly those exploring immunity and the field (immunity tests, protein profiles for example) will make it possible to monitor progress and guide treatment.
La posologie variable selon le produit utilisé et l'affection en cause peut s'échelonner si l'on a recours par exemple à la voie orale de un à six ou plus par jour.En effet,en raison de la déconcentration opérée, spécialement lorsqu'il s'agit des déconcentrations du dixmillième et plus de la D.I.Su.,l'absence de tous risques toxiques permet toutes les posologies et toutes les voies d'administration externes et (ou) internes possibles en médecine et (ou) en chirurgie humaine(s) ou animale( 8) ou toute combinaison des différentes voies.L'absence de toxicité de ces produits permet leur usage au long cours, selon des prescriptions par exemple pluriquotidiennes pendant des semaines,des mois ou des années,permettant leur usage en pathologie déclarée aiguë ou chronique,mais aussi en traitement préventif de protection, par exemple pour les populations à risques(épidémie par exemple) ou pour tout le monde pour les maladies dites dégénératives ou dfles à un vieillissement prématuré ou physiologique. The variable dosage depending on the product used and the condition in question can be staggered if one uses, for example, the oral route from one to six or more per day. Indeed, due to the deconcentration effected, especially when '' these are the deconcentrations of the tenth and more of the DISu., the absence of any toxic risks allows all the dosages and all the external and / or internal routes of administration possible in medicine and (or) in surgery human (s) or animal (8) or any combination of the different routes. The absence of toxicity of these products allows their long-term use, according to prescriptions for example multi-daily for weeks, months or years, allowing their use in pathology declared acute or chronic, but also in preventive protective treatment, for example for populations at risk (epidemic for example) or for everyone for so-called degenerative diseases or those caused by premature or physiological aging. than.
la présente demande a encore pour objet les compositions qui contiennent à titre de principe actif au moins un des médicaments décrits ci-dessus. the present application also relates to the compositions which contain, as active principle, at least one of the medicaments described above.
les présentations de ces médicaments peuvent betre solides ou liquides sous toutes les formes pharmaceutiques possibles comme par exemple les comprimés simples ou dragéifiés,les gélules,les gouttes,les ampoules,les flacons,les granulés,les granules,les globules,les pommades,les préparations injectables etc...Elles sont préparées selon les méthodes connues de l'homme de l'art. the presentations of these drugs can be solid or liquid in all possible pharmaceutical forms such as for example simple or coated tablets, capsules, drops, ampoules, vials, granules, granules, globules, ointments, injectable preparations, etc. They are prepared according to methods known to those skilled in the art.
le ou les principes actifs peuvent y être incorporés à tous les véhicules et excipients possibles employés dans les compositions pharmaceutiques tels que le talc,la gomme arabique,le lactose,le glucose,le saccharose,l'eau,l'alcool,le beurre de cacao, le glycérol,les glycérides semisynthétiques solides,la gélatine, la lanoléine,la vaseline officinale,le stéarate de magnésium, l'amidon, les véhicules aqueux ou non,les corps gras d'origine animale ou végétale,les dérivés paraffiniques,les glycols,les divers agents mouillants, dispersants ou émulsifiants,les conservateurs etc... the active ingredient (s) can be incorporated therein into all possible vehicles and excipients used in pharmaceutical compositions such as talc, gum arabic, lactose, glucose, sucrose, water, alcohol, butter cocoa, glycerol, solid semisynthetic glycerides, gelatin, lanolein, petroleum jelly, magnesium stearate, starch, aqueous or non-aqueous vehicles, fatty substances of animal or vegetable origin, paraffinic derivatives, glycols, various wetting agents, dispersants or emulsifiers, preservatives etc ...
les quelques exemples non limitatifs donnés ci-après ne font qu'illustrer l'invention sans la limiter. Ils ne constituent que quelques exemples particuliers. the few nonlimiting examples given below only illustrate the invention without limiting it. They are just a few specific examples.
Exemple 1 l'acide amino 4 méthyl 10 folique(antimétabolite antifolate bien connu) est immunodépresseur à la dose de 1/10 mg par kg de poids corporelpar jour(D.I.Su.).Cette substance se révèle,conformément au procédé décrit,aux doses inférieures ou égales à 10 -3 xl/10 mg(soit 0,0001 mg) par kg de poids corporel et par jour,tre une substance définie par de nouvelles propriétés eubiotique,immunostimuîante et eutrophique-ce dernier caractère se traduisant pour ce produit en raison de son action sur le métabolisme intracellulaire de l'acide folique par un effet antianémique par exemple. Example 1 amino 4 methyl 10 folic acid (well known antifolate antimetabolite) is immunosuppressive at a dose of 1/10 mg per kg of body weight per day (DISu.) This substance is found, according to the process described, at doses less than or equal to 10 -3 xl / 10 mg (i.e. 0.0001 mg) per kg of body weight and per day, being a substance defined by new eubiotic, immunostimulatory and eutrophic properties - this latter characteristic being reflected for this product in because of its action on the intracellular metabolism of folic acid by an anti-anemic effect for example.
Exemple 2 :les sérums "leucotoxiques" ou sérums antilymphocytaires ou encore les immunoglobulines antilymphocytes humains obtenus par hyperimmunisation d'animaux contre les lymphocytes iwxaxxu ou thymocytes humains sont mr7naxss immodéprese seurs à la dose de 20 000 unités lymphocytotoxiques par jour par adulte.Ces produits deviennent conformément à l'invention immunostimulants et eutrophiques aux doses inférieures ou égales à 20 000 xlO 3 soit 20 unités lymphocytotoxiques par jour pour un adulte.Dans~le cas de l'utilisation de ces sérums antitissu, il est possible de créer des stocks de tissus ou souches antigéniques servant à la confection des antiséruma correspondants qui seront ainsi prescrits en fonction de la pathologie à traiter.Ces stocks d'antigênes et d'antisérums pourront être fabri cués de manière industrielle.les antigènes comme les antiséruma seront prescrits selon le même procédé déjà décrit c'est-à-dire en déconcentration supérieure ou égale à la millième partie de la D.I. Example 2: "leukotoxic" or antilymphocytic sera or even human antilymphocyte immunoglobulins obtained by hyperimmunization of animals against iwxaxxu lymphocytes or human thymocytes are mr7naxss immodepreses sors at a dose of 20,000 lymphocytotoxic units per day per adult. These products become according to the invention immunostimulants and eutrophics at doses less than or equal to 20,000 xlO 3 or 20 lymphocytotoxic units per day for an adult. In ~ in the case of the use of these anti-tissue serums, it is possible to create stocks of tissues or antigenic strains used to make the corresponding antiserum which will be prescribed according to the pathology to be treated. These stocks of antigens and antisera can be manufactured industrially. antigens such as antiserum will be prescribed according to the same process already described, i.e. in deconcentration greater than or equal to the thousandth part of the D.I.
Su. de ces produits.Ces antigènes peuvent provenir de l'organisme à traiter lui-mtme ou être sensibilisés par l'agent ou les agents susceptibles d'être à l'origine de la maladie ou d'en modifier le cours ou modifiés par tous procédés chimiques ou physiques.On pourra se contenter des antig8nes-et des antisérums correspondant s-provenant de pa- tients présentant le m8me type de pathologie ou des pathologies cro- ches ou analogues du point de vue clinique ou histologique ou immuno- logique.Su. These antigens can come from the organism to be treated itself or be sensitized by the agent or agents likely to be at the origin of the disease or to modify its course or modified by any process Chemical or physical. We can be satisfied with the corresponding antigens and antisera coming from patients presenting the same type of pathology or with blunt or analogous pathologies from the clinical, histological or immunological point of view.
les substances immunomodulatrices se définissent en biologie par leur propriété à des doses que nous appellerons if ut sww immunomodulantes(notée dans la suite du texte de manière abrégée D.I. immunomodulatory substances are defined in biology by their property at doses that we will call if ut sww immunomodulating (abbreviated in the following text D.I.
M.),de modifier la réponse de l'organisme quelle que soit la nature de cette modification.Malheureusement ces substances posent souvent toute une série de problèmes qui gênent ou empêchent leur utilisation en médecine courante,particulièrement dans les affections relativement béni gnes::coht,toxicité,effets secondaires,voies d'administration,difficultés de préparation etc...Nous proposons le même procédé conformément à la demande d'innovation,c'est-à-dire que nous procédons à la déconcentration de la substance de telle manière qu'à partir de la millième partie de la D.I.M.,îa substance perd sa toxicité rendant possible une administration répétée, par exemple pluriquotidienne pendant plusieurs semaines,mois ou années entratnant par effet de sommation dans le temps malgré la déconcentration utilisée un effet immunostimulant et eutrophique utilisable en thérapeutique courante même pour des affections réputées bénignes(rhinite,rhinopharingite,grippe etc...).M), to modify the response of the organism whatever the nature of this modification. Unfortunately these substances often pose a whole series of problems which hinder or prevent their use in current medicine, particularly in relatively benign affections: coht, toxicity, side effects, routes of administration, difficulties of preparation etc ... We propose the same process in accordance with the demand for innovation, that is to say that we proceed to the deconcentration of the substance of such so that from the thousandth part of the DIM, the substance loses its toxicity making it possible to repeat administration, for example several times a day for several weeks, months or years, resulting in summation effect over time in spite of the deconcentration used an immunostimulatory effect and eutrophic usable in current therapy even for conditions considered benign (rhinitis, rhinopharingitis, flu etc ...).
L'exemple non limitatif donné ci-après illustre l'invention sans la limiter. Il ne constitue qu'un exemple particulier. The nonlimiting example given below illustrates the invention without limiting it. It is only a specific example.
Exemple :le levamisole présente une action immunomodulante à la do se(D.I.M.)de 100 à 150 mg par jour chez l'homme adulte et 2,5 mg à 2 mg par kg de poids corporel par jour chez l'enfant.Malheureusement,l'ap- parition d'effets secondaires néfastes empêchent une utilisation au long cours sans risque.l'administration de la déconcentration égale ou supérieure à la millième partie de la D.I.M. met à l'abri des effets secondaires possibles,permet une prescription au long cours en toute sécurité et ainsi une immunostimulation par effet de sommation. Example: levamisole has an immunomodulating action on the do se (DIM) of 100 to 150 mg per day in adult men and 2.5 mg to 2 mg per kg of body weight per day in children. harmful side effects prevent long-term safe use. Administration of deconcentration equal to or greater than one thousandth part of the DIM protects against possible side effects, allows long-term prescription in complete safety and thus immunostimulation by summation effect.
En fait,toutes les substances immunomodulatrices-qu'elles soient d'origine humaine,animale,végétale,minérale;qu'il s'agisse de produits de synthèse ou d'hémisynthèse-peuvent être utilisées comme substance de base à déconcentrer.Citons à titre d'exemples non limitatifs:le corynebacterium parvum,les produits d'origine bactérienne(par exemple les endotoxines des bacilles gram-négatifs,la fraction lipidique de ces endotoxines,les exotoxines,les fractions ribosomiales,les fractions des mycobactéries, des pseudomonas,des klepsielles etc...);les molécules chimiques(par exemple::le lévamisole,l'isoprinosine,la phytohémagglutine,le guanosine monophosphate cyclique,le polyacide adénylique,l' adénosine monophosphate cyclique,le poly A:U,le diéthyl de thiocarbonate de soude etc...);les produits d'origine leucocytaire(par exemple l'interféron,le facteur T.F. etc...);les hormones(par exemple la thymosine V,le T.H,P.,les hormones thymiques etc...).là encore,en plus de l'action immunosti- mulante générale,ces produits présentent une action trophique sur tel ou tel tissu ou telles ou telles cellules privilégiés(ées),fonc- tion de l'immunopharmacologie et du métabolisme de ces produits,ce qui servira dans le choix des substances à prescrire. In fact, all immunomodulatory substances - be they of human, animal, vegetable or mineral origin; whether synthetic or hemisynthetic - can be used as a basic substance to be deconcentrated. as nonlimiting examples: corynebacterium parvum, products of bacterial origin (for example endotoxins from gram-negative bacilli, the lipid fraction of these endotoxins, exotoxins, ribosomal fractions, fractions of mycobacteria, pseudomonas, klepsials etc ...); chemical molecules (for example: levamisole, isoprinosine, phytohemagglutin, cyclic guanosine monophosphate, poly adenylic acid, cyclic adenosine monophosphate, poly A: U, diethyl de sodium thiocarbonate etc ...); leukocyte origin products (for example interferon, factor TF etc ...); hormones (for example thymosin V, TH, P., thymic hormones etc ...). again, in addition to the immunostimulating action generated Rale, these products have a trophic action on such or such tissue or such or such privileged cells, function of the immunopharmacology and the metabolism of these products, which will serve in the choice of substances to be prescribed.
Ces produits présentent le même type d'activité immirnostimulan- te que celui décrit concernant les produits obtenus par déconcentration des substances de base connues pour leur action immunosuppres sive.la posologie,les voies d'administration,le choix de la substance,les véhicules et excipients,les présentations sont les mêmes que ceux(celles) décrits(tes) pour les produits obtenus par déconcentration des substances de base connues pour leur action ummuno- dépressive. These products exhibit the same type of immunostimulatory activity as that described for the products obtained by deconcentration of the basic substances known for their immunosuppressive action, the dosage, the routes of administration, the choice of the substance, the vehicles and excipients, the presentations are the same as those described for the products obtained by deconcentration of the basic substances known for their immuno-depressive action.
La présente demande a encore pour objet les compositions qui contiennent g titre de principe actif au moins un des médicaments décrits ci-dessus. The present application also relates to the compositions which contain, as active ingredient, at least one of the medicaments described above.
Enfin,les végétaux,les microorganismes uni ou pluricellulaires et les cellules isolées peuvent bénéficier du même procêdé.Il s'agit là encore de déconcentrer au moins à la millième partie de la dose de substance(s) -qui entrasse un dépérissement de la plante,dm microor ganisme ou de la cellule ou l'arrêt ou le ralentissement de leur métabolisme.Par exemple dans les cas des maladies touchant les végétaux,on admistrera soit l'agent causal tel auel ou modifié à des doses égales ou inférieures à la millième partie de la dose entra1nant un effet défavorable sur les plantes ou de la substance ayant des effets analogues sur ces plantes.l'administration se fera par te voie connue de l'homme de l'art (eau d'arrosage,introduction dans l'eau d'irrigation etc...) Finally, plants, single or multicellular microorganisms and isolated cells can benefit from the same process. Here again, it is a question of deconcentrating at least to the thousandth part of the dose of substance (s) which hinder a decline in the plant , dm microor ganism or of the cell or the stop or the slowing down of their metabolism. For example in the case of the diseases touching the plants, one will admire either the causative agent such auel or modified in doses equal or lower than the thousandth part of the dose causing an unfavorable effect on plants or of the substance having similar effects on these plants. Administration will be by the route known to those skilled in the art (water for irrigation, introduction into the irrigation water etc ...)
Claims (7)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8406638A FR2563435A1 (en) | 1984-04-27 | 1984-04-27 | Process which makes it possible to obtain products that increase the defence capacities of biological organisms |
FR8412460A FR2568775A2 (en) | 1984-04-27 | 1984-08-07 | Process for producing products which increase the defence capacities of biological organisms. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8406638A FR2563435A1 (en) | 1984-04-27 | 1984-04-27 | Process which makes it possible to obtain products that increase the defence capacities of biological organisms |
Publications (1)
Publication Number | Publication Date |
---|---|
FR2563435A1 true FR2563435A1 (en) | 1985-10-31 |
Family
ID=9303552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR8406638A Withdrawn FR2563435A1 (en) | 1984-04-27 | 1984-04-27 | Process which makes it possible to obtain products that increase the defence capacities of biological organisms |
Country Status (1)
Country | Link |
---|---|
FR (1) | FR2563435A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2674755A1 (en) * | 1991-04-05 | 1992-10-09 | Thorel Jean Noel | Novel immunostimulatory medicinal compositions |
-
1984
- 1984-04-27 FR FR8406638A patent/FR2563435A1/en not_active Withdrawn
Non-Patent Citations (2)
Title |
---|
THE MERCK INDEX, 1983, page 1321, réf. no. 9055, Merck & Co., Inc., Rohway N.J. (US); * |
THE MERCK INDEX, 1983, pages 859,860, réf. no. 5861, Merck & Co., Inc., Rohway N.J. (US) * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2674755A1 (en) * | 1991-04-05 | 1992-10-09 | Thorel Jean Noel | Novel immunostimulatory medicinal compositions |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1194044B1 (en) | Pharmaceutical or dietetic mushroom-based compositions and their use | |
FR2629716A1 (en) | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION BASED ON DIPHOSPHONIC ACID DERIVATIVE | |
US6660722B2 (en) | Therapeutical treatments | |
US20070224216A1 (en) | Methods and Compositions Related to Antiviral Therapy Using Algae and Cyanobacteria | |
FR2523976A1 (en) | NEW PROTEIN PRODUCT, OBTAINING AND APPLICATION AS A MEDICINE, IN PARTICULAR AN IMMUNOREGULATOR AND ANTIALLERGIC | |
EP0075523B1 (en) | Medicaments based on algae, and formulations thereof | |
EP0001197B1 (en) | Coupling products of cytidine-diphosphocholine and amino compounds, process for their preparation and their pharmaceutical and analytical application | |
WO2021099453A1 (en) | Aqueous liquid extract of spirulina for preventing and/or treating peripheral chemotherapy-induced neuropathies and the symptoms thereof, and corresponding composition and use | |
FR2563435A1 (en) | Process which makes it possible to obtain products that increase the defence capacities of biological organisms | |
FR2550944A1 (en) | PHARMACEUTICAL ASSOCIATION BASED ON TUMOR ANTI-TUMOR ANTIBODIES AND CYTOTOXIC CONJUGATES, APPROPRIATE IN PARTICULAR FOR THE TREATMENT OF CANCER | |
KR20220045167A (en) | How to increase the bioavailability of over-the-counter and pharmaceutical products | |
FR2674755A1 (en) | Novel immunostimulatory medicinal compositions | |
Barlough | Canine giardiasis: a review | |
CA1229566A (en) | Process for the preparation of the active principle of a drug modulating the immune response | |
Pengsaa et al. | Pharmacokinetic investigation of albendazole and praziquantel in Thai children infected with Giardia intestinalis | |
EP0086152B1 (en) | Medicines containing an association of at least one immunotoxine and at least one monovalent carboxylic ionophore | |
US20030031724A1 (en) | Anti-inflammatory composition and method of using same | |
RU2262350C2 (en) | Vaccine for prophylaxis and immunotherapy of human and animal diseases caused by pathogenic and opportunistic gram-negative microorganisms of intestine group and their exotoxins and method for its preparing (variants), immunoglobulin preparation (variant) and method for its preparing, immunobiological preparation polycomponent vaccine | |
EP1224871A2 (en) | Compositions of Padina algae or their extracts, and their applications in foodstuffs or for the culture of molluscs or arthropodes | |
CA2724937C (en) | Medication for the treatment of gastrointestinal ulcers | |
Stogaus et al. | Is oral levamisole immunostimulation in rats mediated by reduced levels of free plasma corticosterone? | |
EP2988757B1 (en) | Treatment of skin injuries associated with auto-immune and inflammatory diseases using the arsenic compound as2o5 | |
Olusi et al. | Effects of levamisole on the immune responses of experimentally malnourished rats | |
WO2003099259A1 (en) | Oleaginous oral antiparasitic compositions | |
CN1300208A (en) | Icecream-type pharmaceutical formulation and process for preparing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RE | Withdrawal of published application |